Author: admin

• Tradeweb and Chainlink recently announced a collaboration to publish the Tradeweb FTSE U.S. Treasury Benchmark Closing Prices on-chain via DataLink, aiming to enhance transparency and accessibility in U.S. Treasury markets by leveraging blockchain technology for real-time, reliable benchmark pricing data.

• This move may accelerate the integration of digital market infrastructure for institutions seeking trusted, continually available Treasury pricing and open the door for tokenized financial products and expanded on-chain market participation.

• We’ll explore how delivering institutional-grade U.S. Treasury data on-chain may influence Tradeweb’s digital asset growth and investment outlook.

Trump’s oil boom is here – pipelines are primed to profit. Discover the 22 US stocks riding the wave.

To be a shareholder in Tradeweb Markets, you need to believe in the ongoing transition of fixed income markets from manual and voice-based to electronic and increasingly digital trading. The recent partnership with Chainlink advances digital infrastructure for U.S. Treasury data, but does not materially alter the biggest short-term catalyst, which remains increasing electronic trading adoption, or the biggest near-term risk, ongoing reliance on voice trading for complex trades during volatile periods.

Of the recent announcements, Tradeweb’s launch of dealer algorithmic execution capabilities for U.S. Treasuries stands out as most relevant. Together with the Chainlink collaboration, this further supports efforts to enhance automation and real-time data, aligning directly with the catalyst of growing electronic and automated trading volumes in core markets.

However, amid these advances, investors should be aware that if voice trading remains entrenched during key market events, it could…

Read the full narrative on Tradeweb Markets (it’s free!)

Tradeweb Markets’ narrative projects $2.6 billion in revenue and $917.7 million in earnings by 2028. This requires 10.6% yearly revenue growth and a $359.9 million earnings increase from current earnings of $557.8 million.

Uncover how Tradeweb Markets’ forecasts yield a $131.87 fair value, a 20% upside to its current price.

Three Simply Wall St Community members provided fair value estimates for Tradeweb ranging from US$61.66 to US$556.37 per share. While opinions are split, the ongoing move toward market electronification is driving strong debate about longer-term revenue growth.

Explore 3 other fair value estimates on Tradeweb Markets – why the stock might be worth 44% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tradeweb Markets research is our analysis highlighting 2 key rewards that could impact your investment decision.

• Our free Tradeweb Markets research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Tradeweb Markets’ overall financial health at a glance.

Our top stock finds are flying under the radar-for now. Get in early:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

GRAIL (GRAL) just posted its third-quarter earnings, highlighting a jump in Galleri test volume and revenue. The announcement also included a partnership with Samsung, aimed at expanding into key Asian markets.

See our latest analysis for GRAIL.

After a string of upbeat quarterly results, partnerships, and a major capital infusion, GRAIL’s momentum has translated directly into the stock’s performance with a remarkable 156.6% share price return over the past 90 days and a 426.3% total shareholder return over the last year. Both recent and longer-term moves suggest investor optimism is building as commercial traction and validation grow.

If you’re curious what other companies are capturing investors’ attention in healthcare, consider discovering See the full list for free.

The recent rally has left many investors wondering: is GRAIL still undervalued given its growth trajectory, or has the current share price already baked in all the future gains?

GRAIL’s most widely followed fair value estimate stands at $61.50, which is significantly below the last close of $83.20. This notable gap highlights diverging expectations and sets up a pivotal discussion around growth, valuation, and future profitability.

Ongoing positive clinical trial results, including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population-scale studies, are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top-line growth.

Read the complete narrative.

What big bets are hiding inside this valuation call? The fair value hangs on ambitious revenue forecasts, eye-catching profit margin shifts, and hope of regulatory green lights. Curious just how bold the assumptions are? Find out what’s driving this price and whether the market has run ahead of the numbers.

Result: Fair Value of $61.50 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, persistent high losses and dependence on regulatory milestones remain key risks. These factors could quickly dampen optimism if progress falters.

Find out about the key risks to this GRAIL narrative.

If you see the story differently or want to do some digging on your own, you can put together your own take in under three minutes. Do it your way

A great starting point for your GRAIL research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Why limit your opportunities to just one company? Keep your edge sharp, spot potential early, and push your portfolio further with exceptional stocks found through Simply Wall Street’s unique screeners.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GRAL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com